Statins and stroke prevention

Hashem M. Shaltoni, Frank M. Yatsu, David C Hess

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Data from studies on the benefits of statins in coronary artery disease patients in preventing recurrent primary and secondary cardiac endpoints, as well as ischemic strokes, imply the potential value of statins in recurrent ischemic stroke prevention without coronary artery disease symptoms or, by extension, primary ischemic stroke prevention. However, data on the latter are lacking, although the ongoing Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study is designed to answer that question. Until these data become available, clinicians are justified in using statins to avert recurrent ischemic strokes due to atherosclerosis, especially if elevated total cholesterol, increased low-density lipoprotein cholesterol, and/or reduced high-density lipoprotein cholesterol, as specified in the National Cholesterol Education Program Third Adult Treatment Panel, are present This article reviews the pathophysiology of atherosclerosis, particularly the major components of atheromas of cholesterol, smooth muscle cells, inflammation, "foam cells," and connective tissue elements. Emphasis is placed on the first three and the results of statin trials in coronary artery disease, as well as the beneficial pleiotrophic effects of statins in ischemic stroke.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalCurrent Atherosclerosis Reports
Volume7
Issue number4
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stroke
Coronary Artery Disease
Cholesterol
Atherosclerosis
Foam Cells
Atherosclerotic Plaques
Hypercholesterolemia
Connective Tissue
LDL Cholesterol
HDL Cholesterol
Smooth Muscle Myocytes
Inflammation
Education

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statins and stroke prevention. / Shaltoni, Hashem M.; Yatsu, Frank M.; Hess, David C.

In: Current Atherosclerosis Reports, Vol. 7, No. 4, 01.01.2005, p. 313-318.

Research output: Contribution to journalReview article

Shaltoni, Hashem M. ; Yatsu, Frank M. ; Hess, David C. / Statins and stroke prevention. In: Current Atherosclerosis Reports. 2005 ; Vol. 7, No. 4. pp. 313-318.
@article{1ca1097a1b63484a8f04eb95c7c5c61c,
title = "Statins and stroke prevention",
abstract = "Data from studies on the benefits of statins in coronary artery disease patients in preventing recurrent primary and secondary cardiac endpoints, as well as ischemic strokes, imply the potential value of statins in recurrent ischemic stroke prevention without coronary artery disease symptoms or, by extension, primary ischemic stroke prevention. However, data on the latter are lacking, although the ongoing Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study is designed to answer that question. Until these data become available, clinicians are justified in using statins to avert recurrent ischemic strokes due to atherosclerosis, especially if elevated total cholesterol, increased low-density lipoprotein cholesterol, and/or reduced high-density lipoprotein cholesterol, as specified in the National Cholesterol Education Program Third Adult Treatment Panel, are present This article reviews the pathophysiology of atherosclerosis, particularly the major components of atheromas of cholesterol, smooth muscle cells, inflammation, {"}foam cells,{"} and connective tissue elements. Emphasis is placed on the first three and the results of statin trials in coronary artery disease, as well as the beneficial pleiotrophic effects of statins in ischemic stroke.",
author = "Shaltoni, {Hashem M.} and Yatsu, {Frank M.} and Hess, {David C}",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s11883-005-0024-2",
language = "English (US)",
volume = "7",
pages = "313--318",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Statins and stroke prevention

AU - Shaltoni, Hashem M.

AU - Yatsu, Frank M.

AU - Hess, David C

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Data from studies on the benefits of statins in coronary artery disease patients in preventing recurrent primary and secondary cardiac endpoints, as well as ischemic strokes, imply the potential value of statins in recurrent ischemic stroke prevention without coronary artery disease symptoms or, by extension, primary ischemic stroke prevention. However, data on the latter are lacking, although the ongoing Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study is designed to answer that question. Until these data become available, clinicians are justified in using statins to avert recurrent ischemic strokes due to atherosclerosis, especially if elevated total cholesterol, increased low-density lipoprotein cholesterol, and/or reduced high-density lipoprotein cholesterol, as specified in the National Cholesterol Education Program Third Adult Treatment Panel, are present This article reviews the pathophysiology of atherosclerosis, particularly the major components of atheromas of cholesterol, smooth muscle cells, inflammation, "foam cells," and connective tissue elements. Emphasis is placed on the first three and the results of statin trials in coronary artery disease, as well as the beneficial pleiotrophic effects of statins in ischemic stroke.

AB - Data from studies on the benefits of statins in coronary artery disease patients in preventing recurrent primary and secondary cardiac endpoints, as well as ischemic strokes, imply the potential value of statins in recurrent ischemic stroke prevention without coronary artery disease symptoms or, by extension, primary ischemic stroke prevention. However, data on the latter are lacking, although the ongoing Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study is designed to answer that question. Until these data become available, clinicians are justified in using statins to avert recurrent ischemic strokes due to atherosclerosis, especially if elevated total cholesterol, increased low-density lipoprotein cholesterol, and/or reduced high-density lipoprotein cholesterol, as specified in the National Cholesterol Education Program Third Adult Treatment Panel, are present This article reviews the pathophysiology of atherosclerosis, particularly the major components of atheromas of cholesterol, smooth muscle cells, inflammation, "foam cells," and connective tissue elements. Emphasis is placed on the first three and the results of statin trials in coronary artery disease, as well as the beneficial pleiotrophic effects of statins in ischemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=27744529065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744529065&partnerID=8YFLogxK

U2 - 10.1007/s11883-005-0024-2

DO - 10.1007/s11883-005-0024-2

M3 - Review article

VL - 7

SP - 313

EP - 318

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 4

ER -